Statins Block Mammalian Target of Rapamycin Pathway: A Possible Novel Therapeutic Strategy for Inflammatory, Malignant and Neurodegenerative Diseases Publisher Pubmed



Lashgari NA¹ ; Roudsari NM¹ ; Zadeh SST² ; Momtaz S^{3, 4, 5} ; Abbasifard M^{6, 7} ; Reiner Z⁸ ; Abdolghaffari AH^{1, 3, 4, 5} ; Sahebkar A^{9, 10, 11, 12} Show Affiliations
Source: Inflammopharmacology Published:2023

Abstract

Inflammation plays a critical role in several diseases such as cancer, gastric, heart and nervous system diseases. Data suggest that the activation of mammalian target of rapamycin (mTOR) pathway in epithelial cells leads to inflammation. Statins, the inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), seem to be able to inhibit the mTOR. Statins are considered to have favorable effects on inflammatory diseases by reducing the complications caused by inflammation and by regulating the inflammatory process and cytokines secretion. This critical review collected data on this topic from clinical, in vivo and in vitro studies published between 1998 and June 2022 in English from databases including PubMed, Google Scholar, Scopus, and Cochrane libraries. © 2022, The Author(s), under exclusive licence to Springer Nature Switzerland AG.